Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

309
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
309
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

469
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
469
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

480
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
480
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

325
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
325
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

300
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
300
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

946
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
946

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).

Arthritis care & research·2026
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

Mutational Profiling Links Biologically Relevant Variants to Multi-Systemic Rosai-Dorfman Disease.

Blood advances·2026
Same author

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.

Nature reviews. Rheumatology·2026
Same author

Significance of positive rheumatoid factor in ANCA-associated vasculitis.

Clinical and experimental rheumatology·2026
Same author

Evaluating the utility of biopsies in tracheobronchial stenosis: an attempt at expanding knowledge on a narrowed issue.

Clinical and experimental rheumatology·2026

Related Experiment Video

Updated: Mar 18, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.4K

Recent advances in understanding and treating vasculitis.

Matthew J Koster1, Kenneth J Warrington1

  • 1Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.

F1000Research
|June 28, 2016
PubMed
Summary

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are serious conditions. B-cell-targeted therapy offers new hope, but optimal treatment strategies require further investigation.

Keywords:
ANCA-associated vasculitidesB-cellsystemic vasculitidesvasculitis

More Related Videos

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.1K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 18, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.4K
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.1K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Area of Science:

  • Immunology
  • Rheumatology
  • Internal Medicine

Background:

  • Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are life-threatening autoimmune diseases.
  • Current treatments for AAVs carry significant short- and long-term adverse effects.
  • B-cell-targeted therapy using anti-CD20 monoclonal antibodies has emerged as a promising treatment.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging treatments for AAVs.
  • To discuss recent advances and ongoing clinical trials in AAV management.
  • To explore future therapeutic possibilities for AAV patients.

Main Methods:

  • Review of current literature on AAV treatments.
  • Analysis of recent clinical trial data for anti-CD20 therapies.
  • Discussion of expert opinions and emerging research findings.

Main Results:

  • Anti-CD20 therapy has significantly altered the AAV treatment landscape.
  • Unanswered questions remain regarding optimal dosing, timing, and long-term effects of B-cell-targeted therapies.
  • Ongoing trials are crucial for refining treatment protocols.

Conclusions:

  • B-cell-targeted therapy represents a major advancement in AAV management.
  • Further research is essential to optimize treatment strategies and minimize adverse effects.
  • Future directions include personalized medicine approaches and novel therapeutic targets.